Life Sciences Transactions

We represent life sciences clients in the full-array of mission-critical transactions, including licensings, collaborations, financings, joint ventures, and mergers and acquisitions. Our clients range from startups to emerging biotechs to established global pharmaceutical companies, as well as venture capital, private equity, and investment banking firms focused on the life sciences industry.

Our life sciences transactions team helps clients build, negotiate, and implement essential strategic transactions with other pharmaceutical, biotech, and diagnostic companies, as well as the academic, government, and nonprofit sectors. We leverage our industry-specific experience to advise clients on transactions to research, develop, and commercialize products and technologies.

Our life sciences transactions experience ranges from early-stage licensing and research deals to strategic development and commercialization collaborations to mergers and acquisitions, public offerings and other exit events. In the course of structuring and negotiating transactions, we provide a wide variety of legal services, including intellectual property, US Food and Drug Administration/regulatory issues, antitrust, tax, and US and global governmental regulations. We assist clients with operational matters such as supply, distribution, clinical trial, and co-promotion agreements, as well as equity investment agreements. We also represent academic institutions and industry partners in licensing technology and sponsored research programs.

Our lawyers represent life sciences companies on product-related acquisitions and divestitures as well as public and private mergers and acquisitions. We handle transactions of varying sizes and of all different types, including asset purchases, stock purchases, tender offers, proxy contests, restructurings, leveraged buyouts, and going-private transactions. We also represent investment banks and commercial banks, venture capital firms, private equity firms, institutional lenders, independent director committees, and management groups in matters related to mergers and acquisitions.

Our team also advises private equity and venture capital firms, as well as nonprofits, on fund formation and other investment vehicles, and we counsel pharmaceutical clients on their participation in these funds.

Globally, our clients include the following:

17 of the top 20 pharmaceutical companies (Source: Pharmaceutical Executive)
Eight of the top 20 biotechnology companies (Source: Genetic Engineering & Biotechnology News)
13 of the top 20 medical device companies (Source: Medical Product Outsourcing)

event

2023年度亚洲生命科学系列网络研讨会

insight

Five Key Commercial Agreements for Early-Stage Life Sciences Companies

blog post

Executive Order Outlines New Federal Biotechnology, Manufacturing Goals

report

Blockbuster
Biologics Review

Quarterly Update

Select Matters Handled by Our Lawyers

Takeda Pharmaceutical Company in its collaboration agreement valued up to $2 billion with Code Biotherapeutics to design and develop gene therapies for rare disease indications
Eli Lilly and Company in its collaboration agreement valued up to $1 billion with Evotec for the discovery of potential drug candidates for the treatment of diabetes and chronic kidney diseases
Biogen Inc. in its collaboration, valued up to $55 million, with TheraPanacea that focuses on multiple therapeutic areas in neuroscience
Regeneron in its license and collaboration agreement with Nykode Therapeutics for the discovery, development, and commercialization of potential new vaccines for cancer and infectious diseases
GlaxoSmithKline GSK in its exclusive license with Arrowhead Pharmaceuticals to develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference therapeutic that is being developed as a treatment for patients with NASH
Takeda Pharmaceutical Company in its agreement with Moderna and the Government of Japan’s Ministry of Health, Labour, and Welfare to import and distribute an additional 50 million doses of Moderna’s mRNA COVID-19 vaccine in Japan
Adira in its license agreement with Intellia to combine Intellia’s CRISPR/Cas9 allogeneic platform with GEMoaB’s switchable, universal CAR T-cell platforms and its co-development and co-funding agreement to develop an allogeneic universal CAR T-cell product for an immuno-oncology indication
Strand Therapeutics in its licensing agreement valued up to $277 million with BeiGene aimed at developing and commercializing Strand’s innovative, multifunctional mRNA treatments for solid tumors
CRISPR Therapeutics in its strategic partnership with Nkarta Inc. to research, develop, and commercialize CRISPR/Cas9 gene-edited cell therapies for cancer
Zai Lab in its cross-border strategic collaboration with Cullinan Management Inc. for the development, manufacturing, and commercialization of CLN-081, a next-generation irreversible EGFR inhibitor for the treatment of non-small cell lung cancer
Merck in its development and commercialization agreement with Gilead Sciences that combine medicines from each company into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV
23andMe in its $400 million acquisition of Lemonaid Health Inc.
uniQure NV in its $59.6 million acquisition of Corlieve Therapeutics
Advanz Pharma in its agreement with Eisai Co. Ltd to acquire rights for the antiseizure drug Zonegran in the European Union, Middle East, Russia, and Australia
FlowMetric Life Sciences Inc. in the sale of its subsidiaries FlowMetric LLC and FlowMetric Europe, S.p.A. to KCAS Bioanalytical and Biomarker Services, a Vitruvian Partners portfolio company
23andMe in its merger with VG Acquisition Corp.
Oncoceutics in its sale up to $450 million to Chimerix
NBE-Therapeutics in its $1.4 billion sale to Boehringer Ingelheim
Third Point Ventures in the $88 million Series D financing of Cambridge Epigenetix
Borealis Ventures in the $45 million Series B financing of Ankyra
Reify Health Inc. in its $220 million Series C financing led by Coatue
Heru Inc. in its $30 million Series A financing led by D1 Capital Partners